



Docket No.: 64609 (70301)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Wolfgang Kreisel

Application No.: 10/559,694

Art Unit: N/A

Filed: December 6, 2005

Examiner: Not Yet Assigned

For: PROPHYLAXIS AND/OR TREATMENT OF PORTAL HYPERTENSION

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications.

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64609 (70301). A duplicate copy of this paper is enclosed.

Dated: March 6, 2006

Respectfully submitted,

By 

John B. Alexander, Ph.D.

Registration No.: 48,399

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/559,694
				Filing Date	December 6, 2005
				First Named Inventor	Wolfgang Kreisel
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	64609 (70301)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	DE-199 61 302	06-21-2001			
	BB	WO-94-28902	12-22-1994	Pfizer Limited		
	BC	WO-02/060449	08-08-2002	Merck Patent GMBH		
	BD	WO-02/062343	08-15-2002	Merck Patent GMBH		
	BE	EP-1 097 711	05-09-2001	Pfizer Limited		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	G. Jackson, et al., "Effects of Sildenafil Citrate on Human Hemodynamics", <u>The American Journal of Cardiology</u> , Vol. 83(5A), March 4, 1999, pp. 13C-20C.	
	CB	M. Rossle, et al., Portale Hypertension, in "Hepatology," 1995, pp. 271-287.	
	CC	G. Garcia-Tsao, "Portal Hypertension", <u>Current Opinion in Gastroenterology</u> , 2003, pp. 250-258.	
	CD	R. Wiest, et al., "The Paradox of Nitric Oxide in Cirrhosis and Portal Hypertension: Too Much, Not Enough", <u>Hepatology</u> , Vol. 35, No. 2, 2002, pp. 478-491.	
	CE	T. D. Boyer, "Pharmacologic Treatment of Portal Hypertension: Past, Present, and Future", <u>Hepatology</u> , Vol. 34, No. 4, 2001, pp. 834-839.	
	CF	H. C. Herrmann, et al., "Hemodynamic Effects of Sildenafil in Men with Severe Coronary Artery Disease", <u>The New England Journal of Medicine</u> , Vol. 342, No. 22, 2000, pp. 1622-1626.	
	CG	R. M. Zusman, et al., "Overall Cardiovascular Profile of Sildenafil Citrate", <u>The American Journal of Cardiology</u> , Vol. 83(5A), 1999, pp. 35C-44C.	
	CH	U. Gresser, et al., "Erectile Dysfunction: Comparison of Efficacy and Side Effects of the PDE-5 Inhibitors Sildenafil, Vardenafil and Tadalafil Review of the Literature", <u>European Journal of Medical Research</u> , Vol. 7, 2002, pp. 435-446.	
	CI	D. T. Manallack, et al., "The Next Generation of Phosphodiesterase Inhibitors: Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases", <u>Journal of Medicinal Chemistry</u> , Vol. 48. No. 10, 2005, pp. 3449-3462.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/559,694
				Filing Date	December 6, 2005
				First Named Inventor	Wolfgang Kreisel
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	64609 (70301)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CJ	Y. H. Jeon, et al., "Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development", <u>CMLS Cellular and Molecular Life Sciences</u> , Vol. 62, 2005, pp. 1198-1220.	
	CK	J. D. Corbin, et al., "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction", <u>Journal of Andrology</u> , Vol. 24, No. 6 Supplement, November/December 2003, pp. S38-S41.	
	CL	J-P. Tasu, et al., "Hepatic Venous Pressure Gradients Measured by Duplex Ultrasound", <u>Clinical Radiology</u> , Vol. 57, 2002, pp. 746-752.	
	CM	K. Haag, et al., "Correlation of Duplex Sonography Findings and Portal Pressure in 375 Patients with Portal Hypertension", <u>American Journal of Roentgenol</u> , Vol. 172, 1999, pp. 631-635.	
	CN	Y. Takase, et al., "Cyclic GMP Phosphodiesterase Inhibitors. 1. The Discovery of a Novel Potent Inhibitor, 4-((3,4-(Methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline", <u>Journal of Medicinal Chemistry</u> , Vol. 36, No. 24, 1993, pp. 3765-3770.	
	CO	Y. Takase, et al., "Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirements of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity", <u>Journal of Medicinal Chemistry</u> , Vol. 37, No. 13, 1994, pp. 2106-2111.	
	CP	A. Albillos, et al., "Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol", <u>Journal of Hepatology</u> , Vol. 27, 1997, pp. 496-504.	
	CQ	S. Chung, "Advances in Endoscopy - Management of bleeding in the cirrhotic patient", <u>Journal of Gastroenterology and Hepatology</u> , Vol. 17, 2002, pp. 355-360.	
	CR	G. McCormack, et al., "A Practical Guide to the Management of Oesophageal Varices", <u>Drugs</u> , Vol. 57, No. 3, 1999, pp. 327-335.	
	CS	I. Colle, et al., "Sildenafil in Rats with Cirrhosis and Portal Hypertension: Systemic and Splanchnic Haemodynamic Effects", <u>Digest. Dis. Week</u> , 2003, p. A-736.	
	CT	I. Colle, et al., "Systemic and Splanchnic Hemodynamic Effects of Sildenafil in Rats with Cirrhosis and Portal Hypertension", <u>Hepatology</u> , Vol. 36, No. 4, 2002, p. 510A.	
	CU	N. Garcia, Jr., et al., "Systemic and Portal Hemodynamic Effects of Sildenafil Citrate", <u>Gastroenterology</u> , Vol. 120, No. 5, p. A378.	
	CV	H. A. Ghofrani, et al., "Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens", <u>Pneumologie</u> , Vol. 56, 2002, pp. 665-672.	
	CW	D. A. Langer, et al., "Nitric oxide and portal hypertension: Interface of vasoreactivity and angiogenesis", <u>Journal of Hepatology</u> , Vol. 44, 2006, pp. 209-216.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

533665